Novo Nordisk’s Type 2 Diabetes Drug Xultophy Approved in the EU

Novo Nordisk Logo

Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults.
Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza). Read more

Novo Nordisk’s Ryzodeg Does The Job With Fewer Injections

Novo Nordisk Logo

Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen for type 2 diabetes patients.
Ryzodeg is a combination of two distinct insulin analogues , insulin degludec (Tresiba) and insulin aspart (Novolog) in the ratio of 70% and 30%, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes. Read more

JDRF and Tidepool Partner to Bring Data to an Open Source Platform for People with Type 1 Diabetes

JDRF New Logo

JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool, a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and continuous glucose monitors (CGMs) through a device agnostic cloud platform. Read more

Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes

Novo Nordisk Logo

Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba (insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba in combination with Novolog (Novorapid) effectively improved long-term glycemic control.
Read more

Lilly and Boehringer Ingelheim’s New Insulin Glargine Approved in the EU

Lilly - Boehringer - logo

The European Commission has granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The European Commission has granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Read more

The End of Finger Pricks? Abbott’s New FreeStyle Libre System Approved for Sale in Europe

Abbott logo

Abbott has received CE Mark for its its revolutionary CGM system, the FreeStyle Libre Flash Glucose Monitoring System, which uses a new glucose sensing technology. The system eliminates the need for routine finger pricks, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed–a key differentiator from current continuous glucose monitoring systems. Read more

Novo Nordisk To Focus On Diabetes, Not Inflammatory Disorders

Novo Nordisk Logo

Novo Nordisk has decided to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing efforts within diabetes prevention and treatment, obesity and diabetes complications.
The decision to discontinue all R&D within inflammatory disorders follows a review of Novo Nordisk’s strategic position in the therapeutic area after… Read more

Diamyd-Licensed Technology Cures Type 1 Diabetes in Mice

Diamyd_logo

Researchers at UCLA have confirmed earlier findings that combinations of GABA and Antigen Based Therapy (ABT) works synergistically as a treatment in the NOD mouse model of type 1 diabetes. Diamyd Medical is the exclusive licensee for the commercialization of UCLA’s GABA technology for metabolic diseases including in diabetes.
Read more

FDA Approves First Test For Diagnosing Type 1 Diabetes

Kronus

The U.S. FDA has allowed marketing of the first zinc transporter 8 autoantibody (ZnT8Ab) test that can help determine if a person has type 1 diabetes and not another type of diabetes. When used with other tests and patient clinical information, the test may help some people with type 1 diabetes receive timely diagnosis and treatment for their disease. Early treatment of type 1 diabetes is important in helping to prevent further deterioration of insulin producing cells. Read more

Subscribe to our Newsletter

Hide me